Painful intervertebral disc degeneration and inflammation: from laboratory evidence to clinical interventions

Abstract

Low back pain (LBP), as a leading cause of disability, is a common musculoskeletal disorder that results in major social and economic burdens. Recent research has identified inflammation and related signaling pathways as important factors in the onset and progression of disc degeneration, a significant contributor to LBP. Inflammatory mediators also play an indispensable role in discogenic LBP. The suppression of LBP is a primary goal of clinical practice but has not received enough attention in disc research studies. Here, an overview of the advances in inflammation-related pain in disc degeneration is provided, with a discussion on the role of inflammation in IVD degeneration and pain induction. Puncture models, mechanical models, and spontaneous models as the main animal models to study painful disc degeneration are discussed, and the underlying signaling pathways are summarized. Furthermore, potential drug candidates, either under laboratory investigation or undergoing clinical trials, to suppress discogenic LBP by eliminating inflammation are explored. We hope to attract more research interest to address inflammation and pain in IDD and contribute to promoting more translational research.

References

[1] Hartvigsen J et al. What low back pain is and why we need to pay attention. Lancet, 2018, 391:2356-2367

[2] Jackson T et al. Prevalence of chronic pain in low-income and middle-income countries: a systematic review and meta-analysis. Lancet, 2015, 385:S10

[3] Buchbinder R et al. Low back pain: a call for action. Lancet, 2018, 391:2384-2388

[4] Foster NE et al. Prevention and treatment of low back pain: evidence, challenges, and promising directions. Lancet, 2018, 391:2368-2383

[5] Maher C, Underwood M, Buchbinder R. Non-specific low back pain. Lancet, 2017, 389:736-747

[6] Cheung KM et al. Prevalence and pattern of lumbar magnetic resonance imaging changes in a population study of one thousand forty-three individuals. Spine, 2009, 34:934-940

[7] Wuertz K, Haglund L. Inflammatory mediators in intervertebral disk degeneration and discogenic pain. Glob. Spine J., 2013, 3:175-184

[8] Risbud MV, Shapiro IM. Role of cytokines in intervertebral disc degeneration: pain and disc content. Nat. Rev. Rheumatol., 2014, 10:44

[9] Adams MA, Roughley PJ. What is intervertebral disc degeneration, and what causes it? Spine, 2006, 31:2151-2161

[10] Richardson SM et al. Degenerate human nucleus pulposus cells promote neurite outgrowth in neural cells. PloS ONE, 2012, 7

[11] Stefanakis M et al. Annulus fissures are mechanically and chemically conducive to the ingrowth of nerves and blood vessels. Spine, 2012, 37:1883-1891

[12] Khan AN et al. Inflammatory biomarkers of low back pain and disc degeneration: a review. Ann. N.Y. Acad. Sci., 2017, 1410:68-84

[13] Navone SE et al. Inflammatory mediators and signalling pathways controlling intervertebral disc degeneration. Histol. Histopathol., 2017, 32:523-542

[14] Cunha C et al. The inflammatory response in the regression of lumbar disc herniation. Arthritis Res. Ther., 2018, 20:251

[15] Molinos M et al. Inflammation in intervertebral disc degeneration and regeneration. J. R. Soc. Interface, 2015, 12:20141191

[16] Vo NV et al. Molecular mechanisms of biological aging in intervertebral discs. J. Orthop. Res., 2016, 34:1289-1306

[17] Rodrigues-Pinto R, Richardson SM, Hoyland JA. An understanding of intervertebral disc development, maturation and cell phenotype provides clues to direct cell-based tissue regeneration therapies for disc degeneration. Eur. Spine J., 2014, 23:1803-1814

[18] Lyu FJ et al. IVD progenitor cells: a new horizon for understanding disc homeostasis and repair. Nat. Rev. Rheumatol., 2019, 15:102-112

[19] Yang F, Leung VY, Luk KD, Chan D, Cheung KM. Injury-induced sequential transformation of notochordal nucleus pulposus to chondrogenic and fibrocartilaginous phenotype in the mouse. J. Pathol., 2009, 218:113-121

[20] Lv FJ et al. Matrix metalloproteinase 12 is an indicator of intervertebral disc degeneration co-expressed with fibrotic markers. Osteoarthr. Cartil., 2016, 24:1826-1836

[21] Vasiliadis ES, Pneumaticos SG, Evangelopoulos DS, Papavassiliou AG. Biologic treatment of mild and moderate intervertebral disc degeneration. Mol. Med., 2014, 20:400-409

[22] Huang YC, Urban JP, Luk KD. Intervertebral disc regeneration: do nutrients lead the way? Nat. Rev. Rheumatol., 2014, 10:561-566

[23] Bian Q et al. Excessive activation of TGFβ by spinal instability causes vertebral endplate sclerosis. Sci. Rep., 2016, 6

[24] Pandit P, Talbott JF, Pedoia V, Dillon W, Majumdar S. T1ρ and T2‐based characterization of regional variations in intervertebral discs to detect early degenerative changes. J. Orthop. Res., 2016, 34:1373-1381

[25] Arnbak B et al. Identification of subgroups of inflammatory and degenerative MRI findings in the spine and sacroiliac joints: a latent class analysis of 1037 patients with persistent low back pain. Arthritis Res. Ther., 2016, 18:237

[26] Middendorp M et al. Association between intervertebral disc degeneration and the Oswestry Disability Index. J. Back Musculoskelet. Rehabil., 2017, 30:819-823

[27] Arnbak B et al. Prevalence of degenerative and spondyloarthritis-related magnetic resonance imaging findings in the spine and sacroiliac joints in patients with persistent low back pain. Eur. Radiol., 2016, 26:1191-1203

[28] Shamji MF et al. Proinflammatory cytokine expression profile in degenerated and herniated human intervertebral disc tissues. Arthritis Rheum., 2010, 62:1974-1982

[29] Ohtori S, Inoue G, Miyagi M, Takahashi K. Pathomechanisms of discogenic low back pain in humans and animal models. Spine J., 2015, 15:1347-1355

[30] García‐Cosamalón J et al. Intervertebral disc, sensory nerves and neurotrophins: who is who in discogenic pain? J. Anat., 2010, 217:1-15

[31] Coppes M, Marani E, Thomeer R, Oudega M, Groen G. Innervation of annulus fibrosis in low back pain. Lancet, 1990, 336:189-190

[32] Freemont A et al. Nerve ingrowth into diseased intervertebral disc in chronic back pain. Lancet, 1997, 350:178-181

[33] Ohtori S, Miyagi M, Inoue G. Sensory nerve ingrowth, cytokines, and instability of discogenic low back pain: a review. Spine Surg. Relat. Res., 2018, 2:11-17

[34] Lama P, Le Maitre CL, Harding IJ, Dolan P, Adams MA. Nerves and blood vessels in degenerated intervertebral discs are confined to physically disrupted tissue. J. Anat., 2018, 233:86-97

[35] Miyagi M et al. ISSLS Prize winner: Increased innervation and sensory nervous system plasticity in a mouse model of low back pain due to intervertebral disc degeneration. Spine, 2014, 39:1345-1354

[36] Ohtori S et al. Tumor necrosis factor-immunoreactive cells and PGP 9.5-immunoreactive nerve fibers in vertebral endplates of patients with discogenic low back Pain and Modic Type 1 or Type 2 changes on MRI. Spine, 2006, 31:1026-1031

[37] Hayashi S et al. TNF-alpha in nucleus pulposus induces sensory nerve growth: a study of the mechanism of discogenic low back pain using tnf-alpha–deficient mice. Spine, 2008, 33:1542-1546

[38] Alimasi W et al. Regulation of nerve growth factor by anti-inflammatory drugs, a steroid, and a selective cyclooxygenase 2 inhibitor in human intervertebral disc cells stimulated with interleukin-1. Spine, 2013, 38:1466-1472

[39] Evashwick‐Rogler TW et al. Inhibiting tumor necrosis factor‐alpha at time of induced intervertebral disc injury limits long‐term pain and degeneration in a rat model. JOR Spine, 2018, 1

[40] Edgar M. The nerve supply of the lumbar intervertebral disc. J. Bone Jt. Surg. Br., 2007, 89:1135-1139

[41] Krock E, Millecamps M, Currie JB, Stone LS, Haglund L. Low back pain and disc degeneration are decreased following chronic toll-like receptor 4 inhibition in a mouse model. Osteoarthr. Cartil., 2018, 26:1236-1246

[42] Mosley GE, Evashwick-Rogler TW, Lai A, Iatridis JC. Looking beyond the intervertebral disc: the need for behavioral assays in models of discogenic pain. Ann. N. Y. Acad. Sci., 2017, 1409:51-66

[43] Yang G, Liao W, Shen M, Mei H. Insight into neural mechanisms underlying discogenic back pain. J. Int. Med. Res., 2018, 46:4427-4436

[44] Fenty M et al. Novel imaging of the intervertebral disk and pain. Glob. Spine J., 2013, 3:127-132

[45] Boden SD et al. Abnormal magnetic-resonance scans of the cervical spine in asymptomatic subjects. A prospective investigation. J. Bone Jt. Surg. Am., 1990, 72:1178-1184

[46] Vanharanta H et al. Pain provocation and disc deterioration by age. A CT/discography study in a low-back pain population. Spine, 1989, 14:420-423

[47] Peng Y, Lv F-J. Symptomatic versus asymptomatic intervertebral disc degeneration: is inflammation the key? Crit. Rev. Eukaryot. Gene Expr., 2015, 25:13-21

[48] Cho H et al. Snapshot of degenerative aging of porcine intervertebral disc: a model to unravel the molecular mechanisms. Exp. Mol. Med., 2011, 43:334-340

[49] Melrose J et al. Mechanical destabilization induced by controlled annular incision of the intervertebral disc dysregulates metalloproteinase expression and induces disc degeneration. Spine, 2012, 37:18-25

[50] Zhang Y et al. Histological features of the degenerating intervertebral disc in a goat disc-injury model. Spine, 2011, 36:1519-1527

[51] Ganey T, Hutton WC, Moseley T, Hedrick M, Meisel H-J. Intervertebral disc repair using adipose tissue-derived stem and regenerative cells: experiments in a canine model. Spine, 2009, 34:2297-2304

[52] Olmarker K. Puncture of a lumbar intervertebral disc induces changes in spontaneous pain behavior: an experimental study in rats. Spine, 2008, 33:850-855

[53] Nilsson E, Nakamae T, Olmarker K. Pain behavior changes following disc puncture relate to nucleus pulposus rather than to the disc injury per se: an experimental study in rats. Open Orthop. J., 2011, 5:72-77

[54] Kim J-S et al. The rat intervertebral disk degeneration pain model: relationships between biological and structural alterations and pain. Arthritis Res. Ther., 2011, 13:R165

[55] Lee M et al. Complete Freund’s adjuvant-induced intervertebral discitis as an animal model for discogenic low back pain. Anesth. Analg., 2009, 109:1287-1296

[56] Lai A et al. Assessment of functional and behavioral changes sensitive to painful disc degeneration. J. Orthop. Res., 2015, 33:755-764

[57] Lai A et al. Annular puncture with tumor necrosis factor-alpha injection enhances painful behavior with disc degeneration in vivo. Spine J., 2016, 16:420-431

[58] Millecamps M, Stone LS. Delayed onset of persistent discogenic axial and radiating pain after a single-level lumbar intervertebral disc injury in mice. Pain, 2018, 159:1843-1855

[59] Isa ILM et al. Implantation of hyaluronic acid hydrogel prevents the pain phenotype in a rat model of intervertebral disc injury. Sci. Adv., 2018, 4:eaaq0597

[60] Lee S, Millecamps M, Foster DZ, Stone LS. Long-term histological analysis of innervation & macrophage infiltration in a mouse model of intervertebral disc injury-induced low back pain. J. Orthop. Res., 2020, 38:1238-1247

[61] Li Z et al. Both expression of cytokines and posterior annulus fibrosus rupture are essential for pain behavior changes induced by degenerative intervertebral disc: an experimental study in rats. J. Orthop. Res., 2014, 32:262-272

[62] Holguin N, Martin JT, Elliott DM, Judex S. Low-intensity vibrations partially maintain intervertebral disc mechanics and spinal muscle area during deconditioning. Spine J., 2013, 13:428-436

[63] Ao X et al. Development and characterization of a novel bipedal standing mouse model of intervertebral disc and facet joint degeneration. Clin. Orthop. Relat. Res., 2019, 477:1492-1504

[64] Hirata H et al. A rat tail temporary static compression model reproduces different stages of intervertebral disc degeneration with decreased notochordal cell phenotype. J. Orthop. Res., 2014, 32:455-463

[65] Wuertz K et al. In vivo remodeling of intervertebral discs in response to short- and long-term dynamic compression. J. Orthop. Res., 2009, 27:1235-1242

[66] Lotz JC, Colliou OK, Chin JR, Duncan NA, Liebenberg E. Compression-induced degeneration of the intervertebral disc: an in vivo mouse model and finite-element study. Spine, 1998, 23:2493-2506

[67] Stokes IA, McBride CA, Aronsson DD, Roughley PJ. Metabolic effects of angulation, compression, and reduced mobility on annulus fibrosis in a model of altered mechanical environment in scoliosis. Spine Deform., 2013, 1:161-170

[68] Ariga K et al. The relationship between apoptosis of endplate chondrocytes and aging and degeneration of the intervertebral disc. Spine, 2001, 26:2414-2420

[69] Chubinskaya S et al. Anti‐catabolic effect of OP‐1 in chronically compressed intervertebral discs. J. Orthop. Res., 2007, 25:517-530

[70] Miyagi M et al. ISSLS prize winner: disc dynamic compression in rats produces long-lasting increases in inflammatory mediators in discs and induces long-lasting nerve injury and regeneration of the afferent fibers innervating discsa pathomechanism for chronic discogenic low back pain. Spine, 2012, 37:1810-1818

[71] Suzuki M et al. Vertebral compression exacerbates osteoporotic pain in an ovariectomy-induced osteoporosis rat model. Spine, 2013, 38:2085-2091

[72] Fukui D et al. Gait abnormality due to spinal instability after lumbar facetectomy in the rat. Eur. Spine J., 2015, 24:2085-2094

[73] Fukui D et al. Three-dimensional micro-computed tomography analysis for spinal instability after lumbar facetectomy in the rat. Eur. Spine J., 2017, 26:2014-2020

[74] Bian Q et al. Mechanosignaling activation of TGFβ maintains intervertebral disc homeostasis. Bone Res., 2017, 5:17008

[75] Zheng L et al. Ciliary parathyroid hormone signaling activates transforming growth factor-á to maintain intervertebral disc homeostasis during aging. Bone Res., 2018, 6:21

[76] Oichi T et al. A mouse intervertebral disc degeneration model by surgically induced instability. Spine, 2018, 43:E557-E564

[77] Ni S et al. Sensory innervation in porous endplates by Netrin-1 from osteoclasts mediates PGE2-induced spinal hypersensitivity in mice. Nat. Commun., 2019, 10:1-15

[78] Bradshaw AD, Sage EH. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J. Clin. Investig., 2001, 107:1049-1054

[79] Gruber HE, Ingram JA, Leslie K, Hanley EN Jr. Cellular, but not matrix, immunolocalization of SPARC in the human intervertebral disc: decreasing localization with aging and disc degeneration. Spine, 2004, 29:2223-2228

[80] Gruber HE et al. Targeted deletion of the SPARC gene accelerates disc degeneration in the aging mouse. J. Histochem. Cytochem., 2005, 53:1131-1138

[81] James G, Millecamps M, Stone LS, Hodges PW. Dysregulation of the inflammatory mediators in the Multifidus muscle after spontaneous intervertebral disc degeneration SPARC-null mice is ameliorated by physical activity. Spine, 2018, 43:E1184-E1194

[82] Millecamps M, Tajerian M, Sage EH, Stone LS. Behavioural signs of chronic back pain in the SPARC-null mouse. Spine, 2011, 36:95-102

[83] Millecamps M, Tajerian M, Naso L, Sage EH, Stone LS. Lumbar intervertebral disc degeneration associated with axial and radiating low back pain in ageing SPARC-null mice. Pain, 2012, 153:1167-1179

[84] Millecamps M, Czerminski JT, Mathieu AP, Stone LS. Behavioral signs of axial low back pain and motor impairment correlate with the severity of intervertebral disc degeneration in a mouse model. Spine J., 2015, 15:2524-2537

[85] Krock E et al. Interleukin-8 as a therapeutic target for chronic low back pain: Upregulation in human cerebrospinal fluid and pre-clinical validation with chronic reparixin in the SPARC-null mouse model. EBioMedicine, 2019, 43:487-500

[86] Ding H et al. Progranulin derived engineered protein Atsttrin suppresses TNF-alpha-mediated inflammation in intervertebral disc degenerative disease. Oncotarget, 2017, 8:109692-109702

[87] Deng X, Zhao F, Kang B, Zhang X. Elevated interleukin-6 expression levels are associated with intervertebral disc degeneration. Exp. Ther. Med., 2016, 11:1425-1432

[88] Suzuki S et al. Potential involvement of the IL-6/JAK/STAT3 pathway in the pathogenesis of intervertebral disc degeneration. Spine, 2017, 42:E817-E824

[89] Gruber H, Hoelscher G, Ingram J, Norton H, Hanley E Jr. Increased IL-17 expression in degenerated human discs and increased production in cultured annulus cells exposed to IL-1ß and TNF-α. Biotech. Histochem., 2013, 88:302-310

[90] Fontana G, See E, Pandit A. Current trends in biologics delivery to restore intervertebral disc anabolism. Adv. Drug Deliv. Rev., 2015, 84:146-158

[91] Yang H et al. Secreted factors from intervertebral disc cells and infiltrating macrophages promote degenerated intervertebral disc catabolism. Spine, 2019, 44:E520-E529

[92] Wang J et al. Tumor necrosis factor α–and interleukin‐1β–dependent induction of CCL3 expression by nucleus pulposus cells promotes macrophage migration through CCR1. Arthritis Rheum., 2013, 65:832-842

[93] Shen C, Yan J, Jiang L-S, Dai L-Y. Autophagy in rat annulus fibrosus cells: evidence and possible implications. Arthritis Res. Ther., 2011, 13:R132

[94] Purmessur D et al. A role for TNFα in intervertebral disc degeneration: a non-recoverable catabolic shift. Biochem. Biophys. Res. Commun., 2013, 433:151-156

[95] Zhang J et al. TNF‐α enhances apoptosis by promoting chop expression in nucleus pulposus cells: role of the MAPK and NF‐κB pathways. J. Orthop. Res., 2019, 37:697-705

[96] Long J et al. JAG2/Notch2 inhibits intervertebral disc degeneration by modulating cell proliferation, apoptosis, and extracellular matrix. Arthritis Res. Ther., 2019, 21:213

[97] Doita M et al. Influence of macrophage infiltration of herniated disc tissue on the production of matrix metalloproteinases leading to disc resorption. Spine, 2001, 26:1522-1527

[98] Jimbo K, Park JS, Yokosuka K, Sato K, Nagata K. Positive feedback loop of interleukin-1β upregulating production of inflammatory mediators in human intervertebral disc cells in vitro. J. Neurosurg. Spine, 2005, 2:589-595

[99] Le Maitre CL, Freemont AJ, Hoyland JA. The role of interleukin-1 in the pathogenesis of human intervertebral disc degeneration. Arthritis Res. Ther., 2005, 7:R732

[100] Séguin CA, Pilliar RM, Roughley PJ, Kandel RA. Tumor necrosis factorα modulates matrix production and catabolism in nucleus pulposus tissue. Spine, 2005, 30:1940-1948

[101] Le Maitre CL, Hoyland JA, Freemont AJ. Interleukin-1 receptor antagonist delivered directly and by gene therapy inhibits matrix degradation in the intact degenerate human intervertebral disc: an in situ zymographic and gene therapy study. Arthritis Res. Ther., 2007, 9:R83

[102] Bachmeier BE et al. Matrix metalloproteinase expression levels suggest distinct enzyme roles during lumbar disc herniation and degeneration. Eur. Spine J., 2009, 18:1573-1586

[103] Wang J et al. TNF-α and IL-1β promote a disintegrin-like and metalloprotease with thrombospondin type I motif-5-mediated aggrecan degradation through syndecan-4 in intervertebral disc. J. Biol. Chem., 2011, 286:39738-39749

[104] Wang X et al. Tumor necrosis factor-α–and interleukin-1β–dependent matrix metalloproteinase-3 expression in nucleus pulposus cells requires cooperative signaling via syndecan 4 and mitogen-activated protein kinase–NF-κB axis: implications in inflammatory disc disease. Am. J. Pathol., 2014, 184:2560-2572

[105] Tian Y et al. Inflammatory cytokines associated with degenerative disc disease control aggrecanase-1 (ADAMTS-4) expression in nucleus pulposus cells through MAPK and NF-κB. Am. J. Pathol., 2013, 182:2310-2321

[106] Ponnappan RK et al. An organ culture system to model early degenerative changes of the intervertebral disc. Arthritis Res. Ther., 2011, 13:R171

[107] Gorth DJ, Shapiro IM, Risbud MV. Transgenic mice overexpressing human TNF-α experience early onset spontaneous intervertebral disc herniation in the absence of overt degeneration. Cell Death Dis., 2018, 10:7

[108] Gorth DJ, Shapiro IM, Risbud MV. A new understanding of the role of IL-1 in age-related intervertebral disc degeneration in a Murine Model. J. Bone Miner. Res., 2019, 34:1531-1542

[109] Gabr MA et al. Interleukin‐17 synergizes with IFNγ or TNFα to promote inflammatory mediator release and intercellular adhesion molecule‐1 (ICAM‐1) expression in human intervertebral disc cells. J. Orthop. Res., 2011, 29:1-7

[110] Studer RK, Vo N, Sowa G, Ondeck C, Kang J. Human nucleus pulposus cells react to IL-6: independent actions and amplification of response to IL-1 and TNF-α. Spine, 2011, 36:593-599

[111] Bogduk N, Tynan W, Wilson A. The nerve supply to the human lumbar intervertebral discs. J. Anat., 1981, 132 Pt 1 39-56

[112] Grönblad M, Weinstein JN, Santavirta S. Immunohistochemical observations on spinal tissue innervation: a review of hypothetical mechanisms of back pain. Acta Orthop. Scand., 1991, 62:614-622

[113] Fujii K et al. Discogenic back pain: literature review of definition, diagnosis, and treatment. JBMR Plus, 2019, 3

[114] Burke J et al. Intervertebral discs which cause low back pain secrete high levels of proinflammatory mediators. J. Bone Jt. Surg. Br., 2002, 84:196-201

[115] Andrade P et al. Elevated IL-1β and IL-6 levels in lumbar herniated discs in patients with sciatic pain. Eur. Spine J., 2013, 22:714-720

[116] Peng B et al. Possible pathogenesis of painful intervertebral disc degeneration. Spine, 2006, 31:560-566

[117] Richardson SM, Doyle P, Minogue BM, Gnanalingham K, Hoyland JA. Increased expression of matrix metalloproteinase-10, nerve growth factor and substance P in the painful degenerate intervertebral disc. Arthritis Res. Ther., 2009, 11:R126

[118] Krock E et al. Painful, degenerating intervertebral discs up‐regulate neurite sprouting and CGRP through nociceptive factors. J. Cell. Mol. Med., 2014, 18:1213-1225

[119] Aoki Y et al. Disc inflammation potentially promotes axonal regeneration of dorsal root ganglion neurons innervating lumbar intervertebral disc in rats. Spine, 2004, 29:2621-2626

[120] Pezet S, McMahon SB. Neurotrophins: mediators and modulators of pain. Annu. Rev. Neurosci., 2006, 29:507-538

[121] Freemont A et al. Nerve growth factor expression and innervation of the painful intervertebral disc. J. Pathol., 2002, 197:286-292

[122] Safieh‐Garabedian B, Poole S, Allchorne A, Winter J, Woolf CJ. Contribution of interleukin‐1β to the inflammation‐induced increase in nerve growth factor levels and inflammatory hyperalgesia. Br. J. Pharmacol., 1995, 115:1265-1275

[123] Abe Y et al. Proinflammatory cytokines stimulate the expression of nerve growth factor by human intervertebral disc cells. Spine, 2007, 32:635-642

[124] Purmessur D, Freemont AJ, Hoyland JA. Expression and regulation of neurotrophins in the nondegenerate and degenerate human intervertebral disc. Arthritis Res. Ther., 2008, 10:R99

[125] Lee JM et al. Interleukin‐1β induces angiogenesis and innervation in human intervertebral disc degeneration. J. Orthop. Res., 2011, 29:265-269

[126] Gruber H, Hoelscher G, Bethea S, Hanley E Jr. Interleukin 1-beta upregulates brain-derived neurotrophic factor, neurotrophin 3 and neuropilin 2 gene expression and NGF production in annulus cells. Biotech. Histochem., 2012, 87:506-511

[127] Van Tulder M et al. Chapter 3 European guidelines for the management of acute nonspecific low back pain in primary care. Eur. Spine J., 2006, 15:s169-s191

[128] Wuertz K, Vo N, Kletsas D, Boos N. Inflammatory and catabolic signalling in intervertebral discs: the roles of NF-KB and MAP kinases. Eur. Cell Mater., 2012, 23:103-119

[129] Jiao Y et al. Propionibacterium acnes induces discogenic low back pain via stimulating nucleus pulposus cells to secrete pro-algesic factor of IL-8/CINC-1 through TLR2–NF-κB p65 pathway. J. Mol. Med., 2019, 97:25-35

[130] Ahmed AS et al. NF-κB-associated pain-related neuropeptide expression in patients with degenerative disc disease. Int. J. Mol. Sci., 2019, 20:658

[131] Zhang J et al. TGF-β1 suppresses CCL3/4 expression through the ERK signaling pathway and inhibits intervertebral disc degeneration and inflammation-related pain in a rat model. Exp. Mol. Med., 2017, 49

[132] Krock E et al. Nerve growth factor is regulated by toll-like receptor 2 in human intervertebral discs. J. Biol. Chem., 2016, 291:3541-3551

[133] Johnson ZI, Schoepflin ZR, Choi H, Shapiro IM, Risbud MV. Disc in flames: Roles of TNF-α and IL-1β in intervertebral disc degeneration. Eur. Cells Mater., 2015, 30:104-116

[134] Walter BA et al. Reduced tissue osmolarity increases TRPV4 expression and pro-inflammatory cytokines in intervertebral disc cells. Eur. Cell Mater., 2016, 32:123-136

[135] Wagner EF, Nebreda ÁR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat. Rev. Cancer, 2009, 9:537-549

[136] Huang P, Han J, Hui L. MAPK signaling in inflammation-associated cancer development. Protein Cell, 2010, 1:218-226

[137] Kim J-H, Studer R, Vo N, Sowa G, Kang J. p38 MAPK inhibition selectively mitigates inflammatory mediators and VEGF production in AF cells co-cultured with activated macrophage-like THP-1 cells. Osteoarthr. Cartil., 2009, 17:1662-1669

[138] Takeda K, Akira S. Toll-like receptors in innate immunity. Int. Immunol., 2005, 17:1-14

[139] Klawitter M et al. Expression and regulation of toll-like receptors (TLRs) in human intervertebral disc cells. Eur. Spine J., 2014, 23:1878-1891

[140] Li Z et al. Resistin promotes CCL4 expression through toll-like receptor-4 and activation of the p38-MAPK and NF-κB signaling pathways: implications for intervertebral disc degeneration. Osteoarthr. Cartil., 2017, 25:341-350

[141] Gawri R et al. High mechanical strain of primary intervertebral disc cells promotes secretion of inflammatory factors associated with disc degeneration and pain. Arthritis Res. Ther., 2014, 16:R21

[142] Navone S et al. Mechanical loading of intervertebral disc modulates microglia proliferation, activation, and chemotaxis. Osteoarthr. Cartil., 2018, 26:978-987

[143] Tang W et al. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science, 2011, 332:478-484

[144] Phillips KL, Jordan-Mahy N, Nicklin MJ, Le CL. Maitre, Interleukin-1 receptor antagonist deficient mice provide insights into pathogenesis of human intervertebral disc degeneration. Ann. Rheum. Dis., 2013, 72:1860-1867

[145] Mak TW, Saunders ME. The Immune Response, 2006 Burlington Academic Press 463-516

[146] Hao S, Mata M, Glorioso JC, Fink DJ. HSV-mediated expression of interleukin-4 in dorsal root ganglion neurons reduces neuropathic pain. Mol. Pain., 2006, 2

[147] Kedong H, Wang D, Sagaram M, An HS, Chee A. Anti-inflammatory effects of interleukin-4 on intervertebral disc cells. Spine J., 2020, 20:60-68

[148] Yang H et al. TGF-beta1 antagonizes TNF-alpha induced up-regulation of matrix metalloproteinase 3 in nucleus pulposus cells: role of the ERK1/2 pathway. Connect. Tissue Res., 2015, 56:461-468

[149] Echeverry S et al. Transforming growth factor-beta1 impairs neuropathic pain through pleiotropic effects. Mol. Pain., 2009, 5

[150] Williams FM et al. GDF5 single-nucleotide polymorphism rs143383 is associated with lumbar disc degeneration in Northern European women. Arthritis Rheum., 2011, 63:708-712

[151] Li X, Leo BM, Beck G, Balian G, Anderson GD. Collagen and proteoglycan abnormalities in the GDF-5-deficient mice and molecular changes when treating disk cells with recombinant growth factor. Spine, 2004, 29:2229-2234

[152] Shen L, Wu Y, Han L, Zhang H. Overexpression of growth and differentiation factor-5 inhibits inflammatory factors released by intervertebral disc cells. Exp. Ther. Med., 2018, 15:3603-3608

[153] Wei A et al. Expression of growth differentiation factor 6 in the human developing fetal spine retreats from vertebral ossifying regions and is restricted to cartilaginous tissues. J. Orthop. Res., 2016, 34:279-289

[154] Wei A et al. BMP13 prevents the effects of annular injury in an ovine model. Int. J. Biol. Sci., 2009, 5:388-396

[155] Clarke LE et al. Growth differentiation factor 6 and transforming growth factor-beta differentially mediate mesenchymal stem cell differentiation, composition, and micromechanical properties of nucleus pulposus constructs. Arthritis Res. Ther., 2014, 16:R67

[156] Gulati T, Chung SA, Wei AQ, Diwan AD. Localization of bone morphogenetic protein 13 in human intervertebral disc and its molecular and functional effects in vitro in 3D culture. J. Orthop. Res., 2015, 33:1769-1775

[157] Miyazaki S et al. ISSLS PRIZE IN BASIC SCIENCE 2018: Growth differentiation factor-6 attenuated pro-inflammatory molecular changes in the rabbit anular-puncture model and degenerated disc-induced pain generation in the rat xenograft radiculopathy model. Eur. Spine J., 2018, 27:739-751

[158] Cui H et al. Growth differentiation factor-6 attenuates inflammatory and pain-related factors and degenerated disc-induced pain behaviors in rat model. J. Orthop. Res., 2020

[159] Yoon ST et al. ISSLS prize winner: LMP-1 upregulates intervertebral disc cell production of proteoglycans and BMPs in vitro and in vivo. Spine, 2004, 29:2603-2611

[160] Liu H et al. LIM mineralization protein-1 suppresses TNF-alpha induced intervertebral disc degeneration by maintaining nucleus pulposus extracellular matrix production and inhibiting matrix metalloproteinases expression. J. Orthop. Res., 2015, 33:294-303

[161] Ye F et al. Role of SHOX2 in the development of intervertebral disc degeneration. J. Orthop. Res., 2017, 35:1047-1057

[162] Chen Y et al. Melatonin ameliorates intervertebral disc degeneration via the potential mechanisms of mitophagy induction and apoptosis inhibition. J. Cell. Mol. Med., 2019, 23:2136-2148

[163] Chen F et al. Melatonin alleviates intervertebral disc degeneration by disrupting the IL-1β/NF-κB-NLRP3 inflammasome positive feedback loop. Bone Res, 2020, 8:10

[164] Lai A et al. Dietary polyphenols as a safe and novel intervention for modulating pain associated with intervertebral disc degeneration in an in-vivo rat model. PloS ONE, 2019, 14

[165] Li X et al. Resveratrol attenuates inflammation environment-induced nucleus pulposus cell senescence in vitro. Biosci. Rep., 2019, 39:BSR20190126

[166] Gao J, Zhang Q, Song L. Resveratrol enhances matrix biosynthesis of nucleus pulposus cells through activating autophagy via the PI3K/Akt pathway under oxidative damage. Biosci. Rep., 2018, 38:BSR20180544

[167] Jiang Y, Xie Z, Yu J, Fu L. Resveratrol inhibits IL-1beta-mediated nucleus pulposus cell apoptosis through regulating the PI3K/Akt pathway. Biosci. Rep., 2019, 39:BSR20190043

[168] Wang XH et al. Resveratrol attenuated TNF-alpha-induced MMP-3 expression in human nucleus pulposus cells by activating autophagy via AMPK/SIRT1 signaling pathway. Exp. Biol. Med., 2016, 241:848-853

[169] Wuertz K et al. The red wine polyphenol resveratrol shows promising potential for the treatment of nucleus pulposus-mediated pain in vitro and in vivo. Spine, 2011, 36:E1373-E1384

[170] Klawitter M et al. Triptolide exhibits anti-inflammatory, anti-catabolic as well as anabolic effects and suppresses TLR expression and MAPK activity in IL-1β treated human intervertebral disc cells. Eur. Spine J., 2012, 21:850-859

[171] Zhu J et al. Kaempferol slows intervertebral disc degeneration by modifying LPS-induced osteogenesis/adipogenesis imbalance and inflammation response in BMSCs. Int. Immunopharmacol., 2017, 43:236-242

[172] Li K, Li Y, Xu B, Mao L, Zhao J. Sesamin inhibits lipopolysaccharide-induced inflammation and extracellular matrix catabolism in rat intervertebral disc. Connect. Tissue Res., 2016, 57:347-359

[173] Kim JS et al. Lactoferricin mediates anti-inflammatory and anti-catabolic effects via inhibition of IL-1 and LPS activity in the intervertebral disc. J. Cell. Physiol., 2013, 228:1884-1896

[174] Wang X et al. Potential therapeutic role of Co-Q10 in alleviating intervertebral disc degeneration and suppressing IL-1beta-mediated inflammatory reaction in NP cells. Int. Immunopharmacol., 2018, 64:424-431

[175] Ishimoto H et al. In vivo anti-inflammatory and antioxidant properties of ellagitannin metabolite urolithin A. Bioorg. Med. Chem. Lett., 2011, 21:5901-5904

[176] Ryu D et al. Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nat. Med., 2016, 22:879-888

[177] Liu H et al. A inhibits the catabolic effect of TNFalpha on nucleus pulposus cell and alleviates intervertebral disc degeneration in vivo. Front. Pharmacol., 2018, 9:1043

[178] Karppinen J et al. Tumor necrosis factor-alpha monoclonal antibody, infliximab, used to manage severe sciatica. Spine, 2003, 28:750-753

[179] Cohen SP et al. Randomized, double-blind, placebo-controlled, dose-response, and preclinical safety study of transforaminal epidural etanercept for the treatment of sciatica. Anesthesiology, 2009, 110:1116-1126

[180] ClinicalTrials.gov. Infliximab in chronic low back pain and modic changes. https://clinicaltrials.gov/ct2/show/NCT03704363?term=infliximab&cond=low+back+pain&draw=2&rank=1 (2018).

[181] Tsai WC et al. Platelet-rich plasma releasate promotes regeneration and decreases inflammation and apoptosis of injured skeletal muscle. Am. J. Sports Med., 2018, 46:1980-1986

[182] Andia I, Maffulli N. Platelet-rich plasma for managing pain and inflammation in osteoarthritis. Nat. Rev. Rheumatol., 2013, 9:721-730

[183] Akeda K. et al. Intradiscal injection of autologous serum isolated from platelet-rich-plasma for the treatment of discogenic low back pain: preliminary prospective clinical trial. General posters GP141, p. Poster No. 2194 (ISSLS meeting, Gothenburg, Sweden, 2011).

[184] Akeda K et al. Intradiscal injection of autologous platelet-rich plasma releasate to treat discogenic low back pain: a preliminary clinical trial. Asian Spine J., 2017, 11:380-389

[185] Levi D et al. Intradiscal platelet-rich plasma injection for chronic discogenic low back pain: preliminary results from a prospective trial. Pain. Med., 2016, 17:1010-1022

[186] Tuakli-Wosornu YA et al. Lumbar intradiskal platelet-rich plasma (PRP) injections: a prospective, double-blind, randomized controlled study. PM R., 2016, 8:1-10

[187] Lutz GE. Increased nuclear T2 signal intensity and improved function and pain in a patient one year after an intradiscal platelet-rich plasma injection. Pain. Med., 2017, 18:1197-1199

[188] Mantyh PW, Koltzenburg M, Mendell LM, Tive L, Shelton DL. Antagonism of nerve growth factor-TrkA signaling and the relief of pain. Anesthesiology, 2011, 115:189-204

[189] Katz N et al. Efficacy and safety of tanezumab in the treatment of chronic low back pain. Pain, 2011, 152:2248-2258

[190] Kivitz AJ et al. Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain. Pain, 2013, 154:1009-1021

[191] Gimbel JS et al. Long-term safety and effectiveness of tanezumab as treatment for chronic low back pain. Pain, 2014, 155:1793-1801

[192] Hochberg MC et al. When is osteonecrosis not osteonecrosis?: adjudication of reported serious adverse joint events in the tanezumab clinical development program. Arthritis Rheumatol., 2016, 68:382-391

[193] Ho G, Leung VY, Cheung KM, Chan D. Effect of severity of intervertebral disc injury on mesenchymal stem cell-based regeneration. Connect. Tissue Res., 2008, 49:15-21

[194] Lotz J, Fields A, Liebenberg E. The role of the vertebral end plate in low back pain. Glob. Spine J., 2013, 3:153-164

[195] Lv B et al. Relationship between endplate defects, modic change, disc degeneration, and facet joint degeneration in patients with low back pain. Biomed. Res. Int, 2019, 2019:9369853

[196] Bailey JF et al. The relationship between endplate pathology and patient-reported symptoms for chronic low back pain depends on lumbar paraspinal muscle quality. Spine, 2019, 44:1010-1017

[197] Munir S et al. Endplate defect is heritable, associated with low back pain and triggers intervertebral disc degeneration: a longitudinal study from TwinsUK. Spine, 2018, 43:1496-1501

Funding

National Natural Science Foundation of China (National Science Foundation of China)(81772386)